Free Trial
→ The warning signs most investors see too late (From Weiss Ratings) (Ad)tc pixel
NASDAQ:NUWE

Nuwellis Q3 2026 Earnings Date & Estimates

Nuwellis logo
$4.58 -0.08 (-1.72%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$4.48 -0.10 (-2.18%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuwellis is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Nuwellis in Q3 2026

Nuwellis is expected to post earnings of -$122.85 per share on revenue of $2.51 million. In the same quarter a year earlier Nuwellis reported $176.40 per share on revenue of $2.22 million. Nuwellis last reported on August 13, 2026, posting -$239.76 per share and missing the -$214.20 consensus estimate.

Consensus Estimates

Consensus EPS
-$122.85
Expected Revenue
$2.51 million
Prior-Year EPS
$176.40
Prior-Year Revenue
$2.22 million
Expected EPS Growth
-169.6%
Expected Revenue Growth
+13.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$239.76 (Missed by -$25.56)
Last Quarter Revenue
$1.97 million

Prepare for the Q3 2026 Call

Nuwellis Q3 2026 Earnings FAQ

Nuwellis (NASDAQ:NUWE) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Nuwellis' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Nuwellis to post earnings of -$122.85 per share for Q3 2026.

The consensus revenue estimate for Nuwellis is $2.51 million for Q3 2026.

Nuwellis Earnings Headlines

Nuwellis Submits FDA Application To Expand Aquadex Use In Pediatric Patients
November 5 at 2:56 PM  |  rttnews.comhttps://www.rttnews.com/3710662/nuwellis-submits-fda-application-to-expand-aquadex-use-in-pediatric-patients.aspx
Nuwellis Seeks FDA Clearance to Expand Aquadex Use in Pediatric Patients
November 5 at 2:56 PM  |  marketscreener.comM
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
November 8 at 1:00 AM  |  Behind the Markets (Ad)
Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
November 5 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3396441/26106/en/nuwellis-submits-fda-510-k-to-expand-aquadex-smartflow-indication-to-include-pediatric-patients-weighing-5-kg-and-above.html
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
November 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395310/26106/en/nuwellis-to-report-third-quarter-2026-financial-results-on-november-12.html
Nuwellis To Implement 1-for-9 Reverse Stock Split; Stock Down
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3704524/nuwellis-to-implement-1-for-9-reverse-stock-split-stock-down.aspx
See More Nuwellis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuwellis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuwellis and other key companies, straight to your email.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated.

Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs. Nuwellis has also promoted applications of its technology in pediatric care.

The company was formerly known as CHF Solutions, Inc. and adopted the Nuwellis name in 2020. Its products are primarily marketed to hospitals and healthcare providers in the United States. Nuwellis is headquartered in Minneapolis, Minnesota, and focuses on expanding clinical applications and adoption of its ultrafiltration technology.

View Nuwellis Profile
Earnings Tools